Savella: Difference between revisions
From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
Notjusttired (talk | contribs) (→Notable studies: refs) |
Notjusttired (talk | contribs) (add refs, expand, tidy) |
||
Line 1: | Line 1: | ||
'''Savella''' or '''milnacipran''' (generic name) is an antidepressant that is also licensed for use in [[fibromyalgia]]. No studies have been carried out on the effectiveness of Savella in [[ME/CFS]] patients, although off-label use of psychiatric medications in ME/CFS has generally been ineffective.<ref name="Kim2020">{{Cite journal|last=Kim|first=Do-Young|author-link=|last2=Lee|first2=Jin-Seok|author-link2=|last3=Park|first3=Samuel-Young|author-link3=|last4=Kim|first4=Soo-Jin|author-link4=|last5=Son|first5=Chang-Gue|author-link5=|date=2020-01-06|title=Systematic review of randomized controlled trials for chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME)|url=https://doi.org/10.1186/s12967-019-02196-9|journal=Journal of Translational Medicine|volume=18|issue=1|pages=1-12|doi=10.1186/s12967-019-02196-9|issn=1479-5876|pmc = 6943902|pmid=31906979|access-date=|quote=|via=}}</ref> | '''Savella''' or '''milnacipran''' (generic name) is an antidepressant that is also licensed for use in adults with [[fibromyalgia]].<ref name="drugscom-sav">{{Cite web|title =Savella |website=Drugs.com|access-date=2022-01-17|url=https://www.drugs.com/savella.html}}</ref><ref name="drugscom-miln">{{Cite web|title= Milnacipran {{!}} Prescribing information|website=Drugs.com|access-date=2022-01-17|url=https://www.drugs.com/pro/milnacipran.html}}</ref> No studies have been carried out on the effectiveness of Savella in [[ME/CFS]] patients, although off-label use of psychiatric medications in ME/CFS has generally been ineffective.<ref name="Qureshi2021">{{Cite journal|title=Diagnostic Challenges and Management of Fibromyalgia|url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8580749/|journal=Cureus|volume=13|issue=10|pages=e18692|last=Qureshi|first=Aniqa G|last2=Jha|first2=Saurav K|last3=Iskander|first3=John|last4=Avanthika|first4=Chaithanya|last5=Jhaveri|first5=Sharan|last6=Patel|first6=Vithi Hitendra|last7=Rasagna Potini|first7=Bhuvana|last8=Talha Azam|first8=Ahmad|doi=10.7759/cureus.18692|pmc=8580749|pmid=34786265|issn=2168-8184}}</ref><ref name="Kim2020">{{Cite journal|last=Kim|first=Do-Young|author-link=|last2=Lee|first2=Jin-Seok|author-link2=|last3=Park|first3=Samuel-Young|author-link3=|last4=Kim|first4=Soo-Jin|author-link4=|last5=Son|first5=Chang-Gue|author-link5=|date=2020-01-06|title=Systematic review of randomized controlled trials for chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME)|url=https://doi.org/10.1186/s12967-019-02196-9|journal=Journal of Translational Medicine|volume=18|issue=1|pages=1-12|doi=10.1186/s12967-019-02196-9|issn=1479-5876|pmc = 6943902|pmid=31906979|access-date=|quote=|via=}}</ref> | ||
==Theory== | ==Theory== | ||
==Evidence== | ==Evidence== | ||
Savella is an FDA-approved drug for [[fibromyalgia]], with improvements in [[pain]], [[sleep dysfunction|sleep]] and more limited improvements in [[fatigue]]. | Savella is an FDA-approved drug for adults with [[fibromyalgia]],<ref name="PI">{{Cite web|url=https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022256s022lbl.pdf|Savella Patient Information. Reference 4035361.|website=FDA|date=2016}}</ref> with improvements in [[pain]], [[sleep dysfunction|sleep]] and more limited improvements in [[fatigue]]. | ||
No clinical trials have been done for Savella/milnacipran in [[ME/CFS]]. | No clinical trials have been done for Savella/milnacipran in [[ME/CFS]]. | ||
Line 16: | Line 16: | ||
==Notable studies == | ==Notable studies == | ||
*2011, Comparative efficacy and acceptability of amitriptyline, duloxetine and milnacipran in fibromyalgia syndrome: a systematic review with meta-analysis<ref name="Hauser2011">{{Cite journal|title=Comparative efficacy and acceptability of amitriptyline, duloxetine and milnacipran in fibromyalgia syndrome: a systematic review with meta-analysis|date=Mar 2011|url=https://academic.oup.com/rheumatology/article/50/3/532/1790544|journal=Rheumatology (Oxford, England)|volume=50|issue=3|pages=532–543|last=Häuser|first=Winfried|author-link=Winfried Häuser|last2=Petzke|first2=Frank|author-link2=|last3=Üçeyler|first3=Nurcan|author-link3=|last4=Sommer|first4=Claudia|author-link4=|doi=10.1093/rheumatology/keq354|pmc=|pmid=21078630|access-date=|issn=1462-0332|quote=|via=}}</ref> - [https://academic.oup.com/rheumatology/article/50/3/532/1790544 (Full text)] | |||
*2011, Comparative efficacy and acceptability of amitriptyline, duloxetine and milnacipran in fibromyalgia syndrome: a systematic review with meta-analysis<ref name="Hauser2011">{{Cite journal|title=Comparative efficacy and acceptability of amitriptyline, duloxetine and milnacipran in fibromyalgia syndrome: a systematic review with meta-analysis|date=Mar 2011|url=https://academic.oup.com/rheumatology/article/50/3/532/1790544|journal=Rheumatology (Oxford, England)|volume=50|issue=3|pages=532–543|last=Häuser|first=Winfried|author-link=Winfried Häuser|last2=Petzke|first2=Frank|author-link2=|last3=Üçeyler|first3=Nurcan|author-link3=|last4=Sommer|first4=Claudia|author-link4 | |||
*2014, Milnacipran versus other antidepressive agents for depression<ref name="Nakagawa2014">{{Cite journal|title=Milnacipran versus other antidepressive agents for depression|date=2009-07-08|url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4164845/|journal=The Cochrane database of systematic reviews|issue=3|pages=CD006529|last=Nakagawa|first=Atsuo|last2=Watanabe|first2=Norio|last3=Omori|first3=Ichiro M|last4=Barbui|first4=Corrado|last5=Cipriani|first5=Andrea|last6=McGuire|first6=Hugh|last7=Churchill|first7=Rachel|last8=Furukawa|first8=Toshi A|doi=10.1002/14651858.CD006529.pub2|pmc=4164845|pmid=19588396|issn=1469-493X}}</ref> - [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4164845/ (Full text)] | *2014, Milnacipran versus other antidepressive agents for depression<ref name="Nakagawa2014">{{Cite journal|title=Milnacipran versus other antidepressive agents for depression|date=2009-07-08|url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4164845/|journal=The Cochrane database of systematic reviews|issue=3|pages=CD006529|last=Nakagawa|first=Atsuo|last2=Watanabe|first2=Norio|last3=Omori|first3=Ichiro M|last4=Barbui|first4=Corrado|last5=Cipriani|first5=Andrea|last6=McGuire|first6=Hugh|last7=Churchill|first7=Rachel|last8=Furukawa|first8=Toshi A|doi=10.1002/14651858.CD006529.pub2|pmc=4164845|pmid=19588396|issn=1469-493X}}</ref> - [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4164845/ (Full text)] | ||
*2014, Effects of milnacipran on the multidimensional aspects of fatigue and the relationship of fatigue to pain and function: pooled analysis of 3 fibromyalgia trials<ref name="Mease2014">{{Cite journal|title=Effects of Milnacipran on the Multidimensional Aspects of Fatigue and the Relationship of Fatigue to Pain and Function: Pooled Analysis of 3 Fibromyalgia Trials|date=Aug 2014|url=https://journals.lww.com/jclinrheum/Abstract/2014/06000/Effects_of_Milnacipran_on_the_Multidimensional.4.aspx|journal=JCR: Journal of Clinical Rheumatology|volume=20|issue=4|pages=195–202|last=Mease|first=Philip J.|author-link=|last2=Palmer|first2=Robert H.|author-link2=|last3=Wang|first3=Yong|author-link3 | *2014, Effects of milnacipran on the multidimensional aspects of fatigue and the relationship of fatigue to pain and function: pooled analysis of 3 fibromyalgia trials<ref name="Mease2014">{{Cite journal|title=Effects of Milnacipran on the Multidimensional Aspects of Fatigue and the Relationship of Fatigue to Pain and Function: Pooled Analysis of 3 Fibromyalgia Trials|date=Aug 2014|url=https://journals.lww.com/jclinrheum/Abstract/2014/06000/Effects_of_Milnacipran_on_the_Multidimensional.4.aspx|journal=JCR: Journal of Clinical Rheumatology|volume=20|issue=4|pages=195–202|last=Mease|first=Philip J.|author-link=|last2=Palmer|first2=Robert H.|author-link2=|last3=Wang|first3=Yong|author-link3=|language=en-US|doi=10.1097/RHU.0000000000000103|pmc=|pmid=|access-date=|issn=1076-1608|quote=|via=}}</ref> - [https://journals.lww.com/jclinrheum/Fulltext/2014/06000/Effects_of_Milnacipran_on_the_Multidimensional.4.aspx (Full text)] | ||
*2015, Milnacipran for pain in fibromyalgia in adults<ref name="Cording2015">{{Cite journal|title=Milnacipran for pain in fibromyalgia in adults|date=2015-10-20|url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6481368/|journal=The Cochrane Database of Systematic Reviews|volume=2015|issue=10|pages=CD008244|last=Cording|first=Malene|last2=Derry|first2=Sheena|last3=Phillips|first3=Tudor|last4=Moore|first4=R Andrew|last5=Wiffen|first5=Philip J|doi=10.1002/14651858.CD008244.pub3|pmc=6481368|pmid=26482422|issn=1469-493X}}</ref> - [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6481368/ (Full text)] | *2015, Milnacipran for pain in fibromyalgia in adults<ref name="Cording2015">{{Cite journal|title=Milnacipran for pain in fibromyalgia in adults|date=2015-10-20|url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6481368/|journal=The Cochrane Database of Systematic Reviews|volume=2015|issue=10|pages=CD008244|last=Cording|first=Malene|last2=Derry|first2=Sheena|last3=Phillips|first3=Tudor|last4=Moore|first4=R Andrew|last5=Wiffen|first5=Philip J|doi=10.1002/14651858.CD008244.pub3|pmc=6481368|pmid=26482422|issn=1469-493X}}</ref> - [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6481368/ (Full text)] | ||
*2015, Preliminary experience using milnacipran in patients with juvenile fibromyalgia: lessons from a clinical trial program<ref name="Arnold2015">{{Cite journal|title=Preliminary experience using milnacipran in patients with juvenile fibromyalgia: lessons from a clinical trial program|date=2015-06-26|url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4480575/|journal=Pediatric Rheumatology Online Journal|volume=13|issue=|pages=27|last=Arnold|first=Lesley M.|author-link=|last2=Bateman|first2=Lucinda|author-link2=Lucinda Bateman|last3=Palmer|first3=Robert H.|author-link3=|last4=Lin|first4=Yuhua|author-link4 | *2015, Preliminary experience using milnacipran in patients with juvenile fibromyalgia: lessons from a clinical trial program<ref name="Arnold2015">{{Cite journal|title=Preliminary experience using milnacipran in patients with juvenile fibromyalgia: lessons from a clinical trial program|date=2015-06-26|url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4480575/|journal=Pediatric Rheumatology Online Journal|volume=13|issue=|pages=27|last=Arnold|first=Lesley M.|author-link=|last2=Bateman|first2=Lucinda|author-link2=Lucinda Bateman|last3=Palmer|first3=Robert H.|author-link3=|last4=Lin|first4=Yuhua|author-link4=|doi=10.1186/s12969-015-0025-9|pmc=4480575|pmid=26112278|access-date=|issn=1546-0096|quote=|via=}}</ref> - [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4480575/ (Full text)] | ||
*2016, The Effects of Milnacipran on Sleep Disturbance in Fibromyalgia: A Randomized, Double-Blind, Placebo-Controlled, Two-Way Crossover Study<ref name="Ahmed2016">{{Cite journal|title=The Effects of Milnacipran on Sleep Disturbance in Fibromyalgia: A Randomized, Double-Blind, Placebo-Controlled, Two-Way Crossover Study|date=2016-01-15|url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4702190/|journal=Journal of Clinical Sleep Medicine : JCSM : Official Publication of the American Academy of Sleep Medicine|volume=12|issue=1|pages=79–86|last=Ahmed|first=Mansoor|last2=Aamir|first2=Rozina|last3=Jishi|first3=Zahra|last4=Scharf|first4=Martin B.|doi=10.5664/jcsm.5400|pmc=4702190|pmid=26414990|issn=1550-9389}}</ref> - [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4702190/ (Full text)] | *2016, The Effects of Milnacipran on Sleep Disturbance in Fibromyalgia: A Randomized, Double-Blind, Placebo-Controlled, Two-Way Crossover Study<ref name="Ahmed2016">{{Cite journal|title=The Effects of Milnacipran on Sleep Disturbance in Fibromyalgia: A Randomized, Double-Blind, Placebo-Controlled, Two-Way Crossover Study|date=2016-01-15|url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4702190/|journal=Journal of Clinical Sleep Medicine : JCSM : Official Publication of the American Academy of Sleep Medicine|volume=12|issue=1|pages=79–86|last=Ahmed|first=Mansoor|last2=Aamir|first2=Rozina|last3=Jishi|first3=Zahra|last4=Scharf|first4=Martin B.|doi=10.5664/jcsm.5400|pmc=4702190|pmid=26414990|issn=1550-9389}}</ref> - [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4702190/ (Full text)] | ||
Line 33: | Line 31: | ||
*2018, Milnacipran poorly modulates pain in patients suffering from fibromyalgia: a randomized double-blind controlled study<ref name="Pickering2018">{{Cite journal|title=Milnacipran poorly modulates pain in patients suffering from fibromyalgia: a randomized double-blind controlled study|date=2018-08-10|url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6089099/|journal=Drug Design, Development and Therapy|volume=12|pages=2485–2496|last=Pickering|first=Gisèle|last2=Macian|first2=Nicolas|last3=Delage|first3=Noémie|last4=Picard|first4=Pascale|last5=Cardot|first5=Jean-Michel|last6=Sickout-Arondo|first6=Sophia|last7=Giron|first7=Fatiha|last8=Dualé|first8=Christian|last9=Pereira|first9=Bruno|last10=Marcaillou|first10=Fabienne|doi=10.2147/DDDT.S162810|pmc=6089099|pmid=30127596|issn=1177-8881}}</ref> - [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6089099/ (Full text)] | *2018, Milnacipran poorly modulates pain in patients suffering from fibromyalgia: a randomized double-blind controlled study<ref name="Pickering2018">{{Cite journal|title=Milnacipran poorly modulates pain in patients suffering from fibromyalgia: a randomized double-blind controlled study|date=2018-08-10|url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6089099/|journal=Drug Design, Development and Therapy|volume=12|pages=2485–2496|last=Pickering|first=Gisèle|last2=Macian|first2=Nicolas|last3=Delage|first3=Noémie|last4=Picard|first4=Pascale|last5=Cardot|first5=Jean-Michel|last6=Sickout-Arondo|first6=Sophia|last7=Giron|first7=Fatiha|last8=Dualé|first8=Christian|last9=Pereira|first9=Bruno|last10=Marcaillou|first10=Fabienne|doi=10.2147/DDDT.S162810|pmc=6089099|pmid=30127596|issn=1177-8881}}</ref> - [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6089099/ (Full text)] | ||
*2018, Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia<ref name="SNRIs2018">{{Cite journal|title=Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia|date=2018-02-28|url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5846183/|journal=The Cochrane Database of Systematic Reviews|volume=2018|issue=2|pages=CD010292|last=Welsch|first=Patrick|last2=Üçeyler|first2=Nurcan|last3=Klose|first3=Petra|last4=Walitt|first4=Brian|last5=Häuser|first5=Winfried|doi=10.1002/14651858.CD010292.pub2|pmc=5846183|pmid=29489029|issn=1469-493X}}</ref> - [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5846183/ (Full text)] | *2018, Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia<ref name="SNRIs2018">{{Cite journal|title=Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia|date=2018-02-28|url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5846183/|journal=The Cochrane Database of Systematic Reviews|volume=2018|issue=2|pages=CD010292|last=Welsch|first=Patrick|last2=Üçeyler|first2=Nurcan|last3=Klose|first3=Petra|last4=Walitt|first4=Brian|last5=Häuser|first5=Winfried|author-link5=Winfried Häuser|doi=10.1002/14651858.CD010292.pub2|pmc=5846183|pmid=29489029|issn=1469-493X}}</ref> - [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5846183/ (Full text)] | ||
==See also== | ==See also== | ||
*[[Pain]] | |||
*[[Fibromyalgia drugs]] | |||
*[[Depression]] | |||
==Learn more== | ==Learn more== | ||
* | *[https://www.drugs.com/savella.html Savella] - drugs.com | ||
==References== | ==References== |
Revision as of 20:35, January 17, 2022
Savella or milnacipran (generic name) is an antidepressant that is also licensed for use in adults with fibromyalgia.[1][2] No studies have been carried out on the effectiveness of Savella in ME/CFS patients, although off-label use of psychiatric medications in ME/CFS has generally been ineffective.[3][4]
Theory[edit | edit source]
Evidence[edit | edit source]
Savella is an FDA-approved drug for adults with fibromyalgia,[5] with improvements in pain, sleep and more limited improvements in fatigue.
No clinical trials have been done for Savella/milnacipran in ME/CFS.
Clinicians[edit | edit source]
Risks and safety[edit | edit source]
Costs and availability[edit | edit source]
Perscription only drug.
Notable studies[edit | edit source]
- 2011, Comparative efficacy and acceptability of amitriptyline, duloxetine and milnacipran in fibromyalgia syndrome: a systematic review with meta-analysis[6] - (Full text)
- 2014, Milnacipran versus other antidepressive agents for depression[7] - (Full text)
- 2014, Effects of milnacipran on the multidimensional aspects of fatigue and the relationship of fatigue to pain and function: pooled analysis of 3 fibromyalgia trials[8] - (Full text)
- 2015, Milnacipran for pain in fibromyalgia in adults[9] - (Full text)
- 2015, Preliminary experience using milnacipran in patients with juvenile fibromyalgia: lessons from a clinical trial program[10] - (Full text)
- 2016, The Effects of Milnacipran on Sleep Disturbance in Fibromyalgia: A Randomized, Double-Blind, Placebo-Controlled, Two-Way Crossover Study[11] - (Full text)
- 2018, Milnacipran poorly modulates pain in patients suffering from fibromyalgia: a randomized double-blind controlled study[12] - (Full text)
- 2018, Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia[13] - (Full text)
See also[edit | edit source]
Learn more[edit | edit source]
- Savella - drugs.com
References[edit | edit source]
- ↑ "Savella". Drugs.com. Retrieved January 17, 2022.
- ↑ "Milnacipran | Prescribing information". Drugs.com. Retrieved January 17, 2022.
- ↑ Qureshi, Aniqa G; Jha, Saurav K; Iskander, John; Avanthika, Chaithanya; Jhaveri, Sharan; Patel, Vithi Hitendra; Rasagna Potini, Bhuvana; Talha Azam, Ahmad. "Diagnostic Challenges and Management of Fibromyalgia". Cureus. 13 (10): e18692. doi:10.7759/cureus.18692. ISSN 2168-8184. PMC 8580749. PMID 34786265.
- ↑ Kim, Do-Young; Lee, Jin-Seok; Park, Samuel-Young; Kim, Soo-Jin; Son, Chang-Gue (January 6, 2020). "Systematic review of randomized controlled trials for chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME)". Journal of Translational Medicine. 18 (1): 1–12. doi:10.1186/s12967-019-02196-9. ISSN 1479-5876. PMC 6943902. PMID 31906979.
- ↑ FDA (PDF). 2016 https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022256s022lbl.pdf. Text "Savella Patient Information. Reference 4035361." ignored (help); Missing or empty
|title=
(help) - ↑ Häuser, Winfried; Petzke, Frank; Üçeyler, Nurcan; Sommer, Claudia (March 2011). "Comparative efficacy and acceptability of amitriptyline, duloxetine and milnacipran in fibromyalgia syndrome: a systematic review with meta-analysis". Rheumatology (Oxford, England). 50 (3): 532–543. doi:10.1093/rheumatology/keq354. ISSN 1462-0332. PMID 21078630.
- ↑ Nakagawa, Atsuo; Watanabe, Norio; Omori, Ichiro M; Barbui, Corrado; Cipriani, Andrea; McGuire, Hugh; Churchill, Rachel; Furukawa, Toshi A (July 8, 2009). "Milnacipran versus other antidepressive agents for depression". The Cochrane database of systematic reviews (3): CD006529. doi:10.1002/14651858.CD006529.pub2. ISSN 1469-493X. PMC 4164845. PMID 19588396.
- ↑ Mease, Philip J.; Palmer, Robert H.; Wang, Yong (August 2014). "Effects of Milnacipran on the Multidimensional Aspects of Fatigue and the Relationship of Fatigue to Pain and Function: Pooled Analysis of 3 Fibromyalgia Trials". JCR: Journal of Clinical Rheumatology. 20 (4): 195–202. doi:10.1097/RHU.0000000000000103. ISSN 1076-1608.
- ↑ Cording, Malene; Derry, Sheena; Phillips, Tudor; Moore, R Andrew; Wiffen, Philip J (October 20, 2015). "Milnacipran for pain in fibromyalgia in adults". The Cochrane Database of Systematic Reviews. 2015 (10): CD008244. doi:10.1002/14651858.CD008244.pub3. ISSN 1469-493X. PMC 6481368. PMID 26482422.
- ↑ Arnold, Lesley M.; Bateman, Lucinda; Palmer, Robert H.; Lin, Yuhua (June 26, 2015). "Preliminary experience using milnacipran in patients with juvenile fibromyalgia: lessons from a clinical trial program". Pediatric Rheumatology Online Journal. 13: 27. doi:10.1186/s12969-015-0025-9. ISSN 1546-0096. PMC 4480575. PMID 26112278.
- ↑ Ahmed, Mansoor; Aamir, Rozina; Jishi, Zahra; Scharf, Martin B. (January 15, 2016). "The Effects of Milnacipran on Sleep Disturbance in Fibromyalgia: A Randomized, Double-Blind, Placebo-Controlled, Two-Way Crossover Study". Journal of Clinical Sleep Medicine : JCSM : Official Publication of the American Academy of Sleep Medicine. 12 (1): 79–86. doi:10.5664/jcsm.5400. ISSN 1550-9389. PMC 4702190. PMID 26414990.
- ↑ Pickering, Gisèle; Macian, Nicolas; Delage, Noémie; Picard, Pascale; Cardot, Jean-Michel; Sickout-Arondo, Sophia; Giron, Fatiha; Dualé, Christian; Pereira, Bruno; Marcaillou, Fabienne (August 10, 2018). "Milnacipran poorly modulates pain in patients suffering from fibromyalgia: a randomized double-blind controlled study". Drug Design, Development and Therapy. 12: 2485–2496. doi:10.2147/DDDT.S162810. ISSN 1177-8881. PMC 6089099. PMID 30127596.
- ↑ Welsch, Patrick; Üçeyler, Nurcan; Klose, Petra; Walitt, Brian; Häuser, Winfried (February 28, 2018). "Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia". The Cochrane Database of Systematic Reviews. 2018 (2): CD010292. doi:10.1002/14651858.CD010292.pub2. ISSN 1469-493X. PMC 5846183. PMID 29489029.